1. Home
  2. KEEL vs MPLT Comparison

KEEL vs MPLT Comparison

Compare KEEL & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Keel Infrastructure Corp. Common Stock

KEEL

Keel Infrastructure Corp. Common Stock

N/A

Current Price

$4.00

Market Cap

1.9B

Sector

Finance

ML Signal

N/A

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$13.33

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEEL
MPLT
Founded
N/A
2018
Country
Canada
United States
Employees
274
133
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KEEL
MPLT
Price
$4.00
$13.33
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
29.0M
1.4M
Earning Date
N/A
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.17
$9.10
52 Week High
$7.37
$40.43

Technical Indicators

Market Signals
Indicator
KEEL
MPLT
Relative Strength Index (RSI) 37.79 28.78
Support Level $3.41 N/A
Resistance Level $5.03 $20.73
Average True Range (ATR) 0.43 2.62
MACD 0.01 -2.97
Stochastic Oscillator 40.70 15.49

Price Performance

Historical Comparison
KEEL
MPLT

About KEEL Keel Infrastructure Corp. Common Stock

Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: